Albudab based half-life extension services

Albudab based half-life extension services

To overcome the limitation of the short circulating half-life of small biotherapeutics, a large variety of half-life extension strategies have emerged in the last decades. The half-life of albumin-binding antibody (AlbudAb) was widely used to extend the half-lives of short-lived drugs. The AlbudAbs are already utilized to prolong the half-lives of multiple drugs. For example, a fusion protein joining an AlbudAb to exendin-4, a short-duration peptide, has been completed. Following subcutaneous injection, an AlbudAb binds reversibly to albumin to achieve prolonged systemic exposure. The AlbudAbs can potentially be applied to generate a range of long-acting biopharmaceuticals. In addition, AlbudAbs could potentially be used to generate numerous long half-life versions of many short-lived drugs to improve their dosing regimen. Moreover, AlbudAbs have also been proved to increase the half-life of therapeutic molecules via an alternative half-life extension technology utilizing a serum albumin-binding domain antibody genetically fused to the target molecules. For more: https://half-life-extension.creative-biolabs.com/albudab-based-half-life-extension-services.htm